Metastatic NSCLC patients in the real world in Finland
Heikki Ekroos, Olivia Hölsä, Anna Kreutzman, Lila Nikkola, Johanna Vikkula, Riikka Mattila, Aija Knuuttila · 2025
Read Metastatic NSCLC patients in the real world in Finland by Heikki Ekroos, Olivia Hölsä, Anna Kreutzman, Lila Nikkola, Johanna Vikkula, Riikka Mattila, Aija Knuuttila (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12717630.txt.
Description
Heikki Ekroos and six co-authors report, in a 2025 study, how Finns with advanced lung cancer were treated in real clinics. The cancer type is non-small cell lung cancer that has spread. Care has changed fast, with immune drugs and targeted pills joining chemotherapy, and the team wanted a real-world picture from the first years of immune drug use.
They read the records of 646 patients treated at Helsinki University Hospital from 2019 to 2023. The median age was seventy. Survival differed sharply by treatment: a median of eight months on chemotherapy alone, twelve on immune therapy, fourteen on the two joined, and twenty-four on targeted pills. The authors track how drug use shifted over the period.
Catalog record
| CREATOR | Heikki Ekroos, Olivia Hölsä, Anna Kreutzman, Lila Nikkola, Johanna Vikkula, Riikka Mattila, Aija Knuuttila |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |